{"gene":"FH","run_date":"2026-04-28T17:46:03","timeline":{"discoveries":[{"year":2002,"finding":"Germline mutations in the FH gene (encoding fumarate hydratase, a TCA cycle enzyme) cause dominantly inherited uterine fibroids, cutaneous leiomyomata, and papillary renal cell cancer (HLRCC syndrome). Leiomyomatosis-associated mutations predict absent/truncated protein or substitutions of conserved amino acids; fumarate hydratase enzymatic activity is reduced in lymphoblastoid cells from affected individuals and is very low or absent in tumors, establishing FH as a tumor suppressor.","method":"Positional cloning, germline mutation identification, enzymatic activity assay in lymphoblastoid cells and tumor tissue","journal":"Nature genetics","confidence":"High","confidence_rationale":"Tier 1–2 — enzymatic activity measured directly in patient cells and tumors, replicated across multiple families, foundational discovery paper with >1200 citations","pmids":["11865300"],"is_preprint":false},{"year":2002,"finding":"Biallelic inactivation of FH (fumarate hydratase) is rare in sporadic counterparts of HLRCC-associated tumor types; one uterine leiomyosarcoma, one cutaneous leiomyoma, and one soft tissue sarcoma showed biallelic FH inactivation, with the sarcoma representing purely somatic inactivation, confirming FH as a classical two-hit tumor suppressor.","method":"Mutation screening, loss of heterozygosity analysis across multiple tumor types","journal":"Cancer research","confidence":"Medium","confidence_rationale":"Tier 2 — LOH plus sequencing, single study but broad tumor panel","pmids":["12183404"],"is_preprint":false},{"year":2004,"finding":"Somatic FH mutations (a splice site change causing exon 4 deletion and a missense mutation Ala196Thr) occur in nonsyndromic uterine leiomyomas showing LOH at 1q43, confirming FH as a bona fide target of 1q43 deletions and demonstrating that biallelic somatic FH inactivation drives non-hereditary leiomyoma formation.","method":"LOH analysis, Sanger sequencing of FH in 299 malignant tumors and 153 leiomyomas","journal":"The American journal of pathology","confidence":"Medium","confidence_rationale":"Tier 2 — LOH plus mutation sequencing, single study","pmids":["14695314"],"is_preprint":false},{"year":2007,"finding":"FH-deficient (HLRCC) tumors show moderately or highly stabilized HIF1α in 67% of cases, consistent with fumarate accumulation inhibiting prolyl hydroxylases (PHDs) and causing pseudohypoxia; however, HIF1α stabilization in these tumors does not cause microsatellite instability or loss of MSH2, dissociating HIF1α stabilization from mismatch repair deficiency in this context.","method":"Immunohistochemistry for HIF1α and MSH2 in HLRCC tumor series; microsatellite instability analysis","journal":"International journal of cancer","confidence":"Medium","confidence_rationale":"Tier 2 — IHC with functional readout (MSI analysis) on defined tumor cohort, single study","pmids":["17520677"],"is_preprint":false},{"year":2012,"finding":"Fumarate (accumulated due to FH loss) and succinate are competitive inhibitors of multiple α-ketoglutarate (α-KG)-dependent dioxygenases, including histone demethylases (KDMs), TET family 5mC hydroxylases, and prolyl hydroxylases. Knockdown of FH elevates intracellular fumarate which broadly inhibits α-KG-dependent dioxygenase activity; ectopic expression of tumor-derived FH mutants inhibits histone demethylation and 5mC hydroxylation, leading to genome-wide hypermethylation.","method":"In vitro enzymatic inhibition assays, siRNA knockdown of FH with metabolite measurement, ectopic expression of FH mutants, histone methylation and 5-hmC assays","journal":"Genes & development","confidence":"High","confidence_rationale":"Tier 1 — in vitro reconstituted enzyme inhibition plus cellular loss-of-function with orthogonal epigenetic readouts; >900 citations, multiple methods","pmids":["22677546"],"is_preprint":false},{"year":2013,"finding":"Germline FH mutations predispose to malignant pheochromocytoma and paraganglioma. FH-deficient PCC/PGLs show somatic second-hit inactivation, loss of fumarate hydratase enzymatic activity, low 5-hydroxymethylcytosine (5-hmC) levels (consistent with TET inhibition by fumarate), and positive 2SC (S-(2-succino)cysteine) immunostaining indicative of protein succination, demonstrating the same epigenetic deregulation pattern as SDHB-mutated tumors.","method":"Germline sequencing, MLPA for large deletions, immunohistochemistry for 5-hmC and 2SC, enzymatic activity confirmed by second-hit somatic analysis","journal":"Human molecular genetics","confidence":"High","confidence_rationale":"Tier 2 — multi-method (sequencing + IHC biomarkers + enzymatic activity loss), large international cohort, strong evidence","pmids":["24334767"],"is_preprint":false},{"year":2014,"finding":"Proteomic screening of FH-mutant tumors and HLRCC-derived cell lines identified 60 proteins with succinated cysteine residues (S-(2-succino)cysteine, 2SC), a non-enzymatic irreversible modification of cysteine by fumarate. Key succinated targets include GAPDH, KEAP1, and mitochondrial aconitase (ACO2) at functionally significant cysteines; bioinformatic analysis shows most succinated targets are involved in redox signaling, demonstrating that fumarate acts as an oncometabolite through widespread protein succination.","method":"Mass spectrometry-based proteomic succination screen on FH-mutant tumor tissue and HLRCC cell lines","journal":"Metabolites","confidence":"Medium","confidence_rationale":"Tier 1 — MS-based proteomic identification of modification sites, single study on tumor/cell line material","pmids":["25105836"],"is_preprint":false},{"year":2016,"finding":"Homozygous FH knockout in rats is embryonically lethal; heterozygous FH+/- rats display hematopoietic and kidney dysfunction, and small foci of anaplastic tubular epithelial cells in the kidney that are positive for Ki67, p53, and Sox9, demonstrating that partial FH loss causes renal dysplasia and functional organ defects in vivo.","method":"TALEN-mediated FH gene knockout rat model; histopathology, immunohistochemistry (Ki67, p53, Sox9), hematology and biochemical analyses","journal":"Oncotarget","confidence":"Medium","confidence_rationale":"Tier 2 — defined genetic model with multiple phenotypic readouts, single study","pmids":["27556703"],"is_preprint":false},{"year":2016,"finding":"Somatic MED12 mutations and biallelic FH inactivation are mutually exclusive in both HLRCC-associated and sporadic uterine leiomyomas, and FH-deficient tumors cluster separately from MED12-mutant tumors by global gene expression profiling, indicating they represent distinct molecular subtypes driven by different oncogenic pathways.","method":"MED12 mutation screening, 2SC immunohistochemistry for FH deficiency, Affymetrix gene expression arrays","journal":"British journal of cancer","confidence":"Medium","confidence_rationale":"Tier 2 — mutual exclusivity demonstrated across comprehensive tumor series with transcriptomic validation","pmids":["27187686"],"is_preprint":false},{"year":2017,"finding":"MED12, HMGA2, and FH alterations are mutually exclusive driver alterations in uterine smooth muscle tumors. FH-deficient tumors are the predominant driver in leiomyomas with bizarre nuclei, while MED12 mutations predominate in conventional and mitotically active leiomyomas; presence of these leiomyoma driver alterations in ~one-third of leiomyosarcomas suggests potential progression from precursor lesions.","method":"FH immunohistochemistry (2SC), MED12 mutation screening, HMGA2 expression analysis across 210 uterine smooth muscle tumors","journal":"Molecular cancer","confidence":"Medium","confidence_rationale":"Tier 2 — large tumor series with multiple molecular assays, single study","pmids":["28592321"],"is_preprint":false},{"year":2021,"finding":"FH encodes a mitochondrial enzyme catalyzing the reversible hydration of fumarate to L-malate in the TCA cycle. FH deficiency drives oncogenesis through multiple mechanisms: promotion of aerobic glycolysis (Warburg effect), induction of pseudohypoxia (via PHD inhibition and HIF stabilization), post-translational protein succination, and impairment of DNA damage repair by homologous recombination.","method":"Review synthesizing mechanistic experimental data from multiple prior studies","journal":"Journal of clinical pathology","confidence":"Medium","confidence_rationale":"Tier 3 — comprehensive review synthesizing established mechanisms; mechanistic claims grounded in cited experimental literature","pmids":["34353877"],"is_preprint":false},{"year":2022,"finding":"HIRA loss enhances proliferation and invasion of Fh1-deficient cells in vitro and in vivo. Mechanistically, Hira loss activates MYC and its target genes, specifically increasing nucleotide metabolism in Fh1-deficient cells independent of HIRA's histone chaperone activity, identifying a synthetic vulnerabilty in FH-deficient cells.","method":"Genome-wide CRISPR-Cas9 screen in Fh1-deficient mouse cells; in vitro proliferation/invasion assays; in vivo tumor models; transcriptomic analysis of MYC targets; nucleotide metabolism assays","journal":"Science advances","confidence":"High","confidence_rationale":"Tier 1–2 — genome-wide unbiased CRISPR screen plus mechanistic follow-up with multiple orthogonal methods in vitro and in vivo","pmids":["36269833"],"is_preprint":false},{"year":2023,"finding":"Fumarate accumulation due to FH loss blocks de novo purine biosynthesis, rendering FH-deficient cells dependent on the purine salvage pathway for proliferation. Genetic or pharmacologic inhibition of purine salvage (including 6-mercaptopurine) reduced HLRCC tumor growth in vivo. Functional characterization of 74 FH variants of uncertain significance showed that over half are enzymatically inactive.","method":"Catalytic efficiency measurement of 74 FH variants; isotope tracing of purine biosynthesis; genetic knockdown and pharmacologic inhibition of purine salvage in HLRCC cell lines; in vivo xenograft models","journal":"Cancer discovery","confidence":"High","confidence_rationale":"Tier 1 — in vitro enzymatic assays for 74 variants plus metabolic tracing plus in vivo validation; multiple orthogonal methods","pmids":["37255402"],"is_preprint":false},{"year":2023,"finding":"FH loss, via fumarate accumulation, activates multiple oncogenic cascades contributing to tumorigenesis including pseudohypoxia, epigenetic reprogramming through α-KG-dependent dioxygenase inhibition, protein succination, and metabolic rewiring; the tissue-specific aggressive behavior of HLRCC cancers remains under investigation.","method":"Review integrating mechanistic experimental findings from the field","journal":"British journal of cancer","confidence":"Medium","confidence_rationale":"Tier 3 — comprehensive mechanistic review; individual mechanisms grounded in cited experimental work","pmids":["37689804"],"is_preprint":false},{"year":2011,"finding":"Novel FH mutations across 56 HLRCC families and isolated papillary RCC patients demonstrated that all 21 novel mutations are deleterious by significant reduction of FH enzymatic activity; reduced FH activity was the functional correlate for pathogenicity of missense, frameshift, nonsense, splice site, and deletion variants.","method":"Sanger sequencing, functional FH enzymatic activity assay in patient-derived samples","journal":"Journal of medical genetics","confidence":"Medium","confidence_rationale":"Tier 1–2 — direct enzymatic activity measurement for novel variants, large clinical series","pmids":["21398687"],"is_preprint":false}],"current_model":"FH (fumarate hydratase) is a mitochondrial TCA cycle enzyme that catalyzes the reversible hydration of fumarate to L-malate; germline loss-of-function mutations cause HLRCC by acting as a classical two-hit tumor suppressor, with the resulting fumarate accumulation driving oncogenesis through competitive inhibition of α-KG-dependent dioxygenases (causing histone/DNA hypermethylation and pseudohypoxia), widespread protein succination of cysteine residues (modifying GAPDH, KEAP1, ACO2 and ~60 other proteins), blockade of de novo purine biosynthesis forcing purine salvage pathway dependence, and impairment of homologous recombination DNA repair—while complete FH loss is embryonically lethal and HIRA co-loss specifically activates MYC-driven nucleotide metabolism as a synthetic vulnerability in FH-deficient tumors."},"narrative":{"teleology":[{"year":2002,"claim":"Positional cloning established FH as the causative gene for HLRCC syndrome and demonstrated that germline mutations abolish or reduce fumarate hydratase enzymatic activity, identifying the first TCA cycle enzyme to function as a bona fide tumor suppressor.","evidence":"Linkage mapping, mutation identification, and enzymatic activity assays in patient lymphoblastoid cells and tumors across multiple HLRCC families","pmids":["11865300","12183404"],"confidence":"High","gaps":["Mechanism by which loss of a metabolic enzyme drives tumorigenesis was unknown","Whether FH loss contributes to sporadic (non-syndromic) tumors was unclear","No animal model existed to test consequences of FH loss in vivo"]},{"year":2004,"claim":"The discovery of biallelic somatic FH inactivation in sporadic uterine leiomyomas confirmed FH as a driver of non-hereditary tumors and showed that FH-deficient leiomyomas represent a distinct molecular subtype from MED12-mutant tumors.","evidence":"LOH analysis and Sanger sequencing of FH in sporadic leiomyomas; later confirmed by mutual exclusivity with MED12 and HMGA2 alterations across large tumor series","pmids":["14695314","27187686","28592321"],"confidence":"Medium","gaps":["Whether FH-deficient leiomyomas can progress to leiomyosarcoma remained uncertain","Tissue-specific mechanisms favoring smooth muscle tumorigenesis were not defined"]},{"year":2007,"claim":"Demonstration of HIF1α stabilization in FH-deficient tumors provided the first evidence that fumarate accumulation inhibits prolyl hydroxylases to create pseudohypoxia, linking metabolite accumulation to an oncogenic signaling phenotype.","evidence":"HIF1α immunohistochemistry in HLRCC tumor series with microsatellite instability analysis","pmids":["17520677"],"confidence":"Medium","gaps":["Whether HIF1α stabilization was the primary oncogenic driver or one of several parallel mechanisms was unclear","Direct measurement of PHD inhibition by fumarate in these tumors was lacking"]},{"year":2011,"claim":"Systematic functional characterization of 21 novel FH mutations confirmed that reduced enzymatic activity is the universal pathogenic mechanism across all mutation types, establishing a functional assay framework for variant classification.","evidence":"Sanger sequencing and direct FH enzymatic activity assay across 56 HLRCC families","pmids":["21398687"],"confidence":"Medium","gaps":["Many variants of uncertain significance remained uncharacterized","Quantitative relationship between residual FH activity and tumor risk was not established"]},{"year":2012,"claim":"The mechanistic basis of fumarate-driven oncogenesis was broadened beyond pseudohypoxia by demonstrating that fumarate competitively inhibits the entire family of α-KG-dependent dioxygenases, including histone demethylases and TET enzymes, causing genome-wide epigenetic reprogramming.","evidence":"In vitro enzymatic inhibition assays, siRNA knockdown of FH with metabolite quantification, ectopic expression of tumor-derived FH mutants with histone methylation and 5-hmC readouts","pmids":["22677546"],"confidence":"High","gaps":["Which specific epigenetic changes are causally required for transformation versus bystanders was not resolved","Whether epigenetic changes are reversible upon FH reconstitution was not tested"]},{"year":2013,"claim":"FH was established as a pheochromocytoma/paraganglioma susceptibility gene with the same fumarate-driven epigenetic and succination signatures as seen in SDH-mutant tumors, expanding the clinical spectrum of FH deficiency beyond HLRCC.","evidence":"Germline sequencing, MLPA, immunohistochemistry for 5-hmC and 2SC in FH-mutant PCC/PGL cohort","pmids":["24334767"],"confidence":"High","gaps":["Why FH mutations only rarely cause PCC/PGL compared to SDH mutations was unexplained","Genotype-phenotype correlations distinguishing HLRCC-only from HLRCC+PCC/PGL families were not established"]},{"year":2014,"claim":"Proteomic profiling revealed that fumarate-mediated protein succination is widespread (~60 targets), irreversibly modifying functionally critical cysteines on GAPDH, KEAP1, and ACO2, establishing protein succination as a major effector mechanism of FH-deficient oncogenesis alongside epigenetic reprogramming.","evidence":"Mass spectrometry-based succination screen on FH-mutant tumor tissue and HLRCC cell lines","pmids":["25105836"],"confidence":"Medium","gaps":["The individual contributions of specific succination events to tumorigenesis were not dissected","Whether succination targets differ across tissue types was not tested"]},{"year":2016,"claim":"An FH-knockout rat model demonstrated that complete FH loss is embryonically lethal while heterozygous loss causes renal dysplasia and hematopoietic defects, providing the first in vivo genetic evidence that partial FH deficiency has cell-autonomous pathological consequences in kidney epithelium.","evidence":"TALEN-mediated FH knockout in rats with histopathology, IHC, and hematologic/biochemical analysis","pmids":["27556703"],"confidence":"Medium","gaps":["The rat model did not recapitulate frank tumor formation characteristic of HLRCC","Whether the renal dysplastic foci progress to carcinoma with aging was not determined"]},{"year":2022,"claim":"A genome-wide CRISPR screen identified HIRA loss as a synthetic vulnerability partner in FH-deficient cells, operating through MYC activation and enhanced nucleotide metabolism independent of HIRA's histone chaperone function, revealing a non-canonical cooperation between chromatin regulation and metabolic rewiring.","evidence":"CRISPR-Cas9 screen in Fh1-null mouse cells; in vitro/in vivo validation; transcriptomic and nucleotide metabolism assays","pmids":["36269833"],"confidence":"High","gaps":["Whether HIRA loss occurs spontaneously in human HLRCC tumors was not established","The mechanism linking HIRA loss to MYC activation was not fully defined","Therapeutic targeting of this synthetic interaction was not demonstrated"]},{"year":2023,"claim":"Fumarate accumulation was shown to block de novo purine biosynthesis by inhibiting adenylosuccinate lyase, creating a targetable dependence on the purine salvage pathway that was exploited therapeutically with 6-mercaptopurine in vivo; in parallel, systematic enzymatic characterization of 74 FH variants of uncertain significance classified over half as pathogenic.","evidence":"Isotope tracing of purine metabolism, enzymatic characterization of 74 FH variants, genetic and pharmacologic purine salvage inhibition in HLRCC xenografts","pmids":["37255402"],"confidence":"High","gaps":["Clinical efficacy of purine salvage inhibition in HLRCC patients has not been tested","Whether purine synthesis blockade cooperates with epigenetic or succination mechanisms in driving tumor phenotypes is unresolved"]},{"year":null,"claim":"The tissue-specific determinants of aggressive FH-deficient tumorigenesis (e.g., why HLRCC renal tumors are particularly lethal) and the relative causal contributions of epigenetic reprogramming, protein succination, and metabolic rewiring to tumor initiation versus progression remain unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No genetically faithful HLRCC mouse model recapitulates full-spectrum renal cell carcinoma","Causal hierarchy among pseudohypoxia, epigenetic changes, succination, and purine metabolism disruption is not established","Tissue-specific cofactors that determine tumor spectrum in FH mutation carriers are unknown"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0016829","term_label":"lyase activity","supporting_discovery_ids":[0,4,12,14]}],"localization":[{"term_id":"GO:0005739","term_label":"mitochondrion","supporting_discovery_ids":[0,10]}],"pathway":[{"term_id":"R-HSA-1430728","term_label":"Metabolism","supporting_discovery_ids":[0,4,12]},{"term_id":"R-HSA-4839726","term_label":"Chromatin organization","supporting_discovery_ids":[4,5]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[0,5,12]}],"complexes":[],"partners":["KEAP1","GAPDH","ACO2","HIRA","HIF1A"],"other_free_text":[]},"mechanistic_narrative":"FH encodes fumarate hydratase, a mitochondrial TCA cycle enzyme that catalyzes the reversible hydration of fumarate to L-malate and functions as a tumor suppressor whose biallelic inactivation drives oncogenesis through accumulation of the oncometabolite fumarate. Fumarate competitively inhibits α-ketoglutarate-dependent dioxygenases—including histone demethylases (KDMs), TET hydroxylases, and prolyl hydroxylases—causing genome-wide DNA and histone hypermethylation and pseudohypoxic HIF1α stabilization, while also non-enzymatically succinating cysteine residues on ~60 proteins including GAPDH, KEAP1, and ACO2 [PMID:22677546, PMID:25105836]. Germline heterozygous FH loss-of-function mutations cause hereditary leiomyomatosis and renal cell cancer (HLRCC) syndrome, with tumors showing classical two-hit inactivation and near-complete loss of enzymatic activity [PMID:11865300, PMID:21398687], and also predispose to pheochromocytoma and paraganglioma [PMID:24334767]. FH deficiency blocks de novo purine biosynthesis, creating dependence on the purine salvage pathway that represents a therapeutic vulnerability, while co-deletion of the histone chaperone HIRA activates MYC-driven nucleotide metabolism as an additional synthetic vulnerability in FH-null cells [PMID:37255402, PMID:36269833]."},"prefetch_data":{"uniprot":{"accession":"P07954","full_name":"Fumarate hydratase, mitochondrial","aliases":[],"length_aa":510,"mass_kda":54.6,"function":"Catalyzes the reversible stereospecific interconversion of fumarate to L-malate (PubMed:30761759). Experiments in other species have demonstrated that specific isoforms of this protein act in defined pathways and favor one direction over the other (Probable) Catalyzes the hydration of fumarate to L-malate in the tricarboxylic acid (TCA) cycle to facilitate a transition step in the production of energy in the form of NADH Catalyzes the dehydration of L-malate to fumarate (By similarity). Fumarate metabolism in the cytosol plays a role during urea cycle and arginine metabolism; fumarate being a by-product of the urea cycle and amino-acid catabolism (By similarity). Also plays a role in DNA repair by promoting non-homologous end-joining (NHEJ) (PubMed:20231875, PubMed:26237645). In response to DNA damage and phosphorylation by PRKDC, translocates to the nucleus and accumulates at DNA double-strand breaks (DSBs): acts by catalyzing formation of fumarate, an inhibitor of KDM2B histone demethylase activity, resulting in enhanced dimethylation of histone H3 'Lys-36' (H3K36me2) (PubMed:26237645)","subcellular_location":"Cytoplasm, cytosol; Nucleus; Chromosome","url":"https://www.uniprot.org/uniprotkb/P07954/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/FH","classification":"Not Classified","n_dependent_lines":245,"n_total_lines":1208,"dependency_fraction":0.20281456953642385},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/FH","total_profiled":1310},"omim":[{"mim_id":"621245","title":"PIGGYBAC TRANSPOSABLE ELEMENT-DERIVED GENE 4; PGBD4","url":"https://www.omim.org/entry/621245"},{"mim_id":"621244","title":"PIGGYBAC TRANSPOSABLE ELEMENT-DERIVED GENE 1; PGBD1","url":"https://www.omim.org/entry/621244"},{"mim_id":"620990","title":"ACTH-INDEPENDENT MACRONODULAR ADRENAL HYPERPLASIA 3; AIMAH3","url":"https://www.omim.org/entry/620990"},{"mim_id":"620712","title":"POLYDACTYLY-MACROCEPHALY SYNDROME; PDMCS","url":"https://www.omim.org/entry/620712"},{"mim_id":"620684","title":"HGH1 HOMOLOG; HGH1","url":"https://www.omim.org/entry/620684"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Mitochondria","reliability":"Supported"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in all","driving_tissues":[{"tissue":"liver","ntpm":252.7}],"url":"https://www.proteinatlas.org/search/FH"},"hgnc":{"alias_symbol":[],"prev_symbol":[]},"alphafold":{"accession":"P07954","domains":[{"cath_id":"1.10.275.10","chopping":"49-183","consensus_level":"high","plddt":98.2528,"start":49,"end":183},{"cath_id":"1.20.200.10","chopping":"189-441","consensus_level":"high","plddt":98.1368,"start":189,"end":441},{"cath_id":"1.10.40.30","chopping":"453-504","consensus_level":"high","plddt":98.0544,"start":453,"end":504}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P07954","model_url":"https://alphafold.ebi.ac.uk/files/AF-P07954-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P07954-F1-predicted_aligned_error_v6.png","plddt_mean":92.69},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=FH","jax_strain_url":"https://www.jax.org/strain/search?query=FH"},"sequence":{"accession":"P07954","fasta_url":"https://rest.uniprot.org/uniprotkb/P07954.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P07954/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P07954"}},"corpus_meta":[{"pmid":"11865300","id":"PMC_11865300","title":"Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer.","date":"2002","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/11865300","citation_count":1204,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22677546","id":"PMC_22677546","title":"Inhibition of α-KG-dependent histone and DNA demethylases by fumarate and succinate that are accumulated in mutations of FH and SDH tumor suppressors.","date":"2012","source":"Genes & development","url":"https://pubmed.ncbi.nlm.nih.gov/22677546","citation_count":920,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24334767","id":"PMC_24334767","title":"Germline mutations in FH confer predisposition to malignant pheochromocytomas and paragangliomas.","date":"2013","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/24334767","citation_count":315,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26214741","id":"PMC_26214741","title":"LEF-1 and TCF-1 orchestrate T(FH) differentiation by regulating differentiation circuits upstream of the transcriptional repressor Bcl6.","date":"2015","source":"Nature immunology","url":"https://pubmed.ncbi.nlm.nih.gov/26214741","citation_count":286,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26214740","id":"PMC_26214740","title":"The transcription factor TCF-1 initiates the differentiation of T(FH) cells during acute viral infection.","date":"2015","source":"Nature immunology","url":"https://pubmed.ncbi.nlm.nih.gov/26214740","citation_count":198,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29444980","id":"PMC_29444980","title":"Circulating TFH cells, serological memory, and tissue compartmentalization shape human influenza-specific B cell immunity.","date":"2018","source":"Science translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/29444980","citation_count":191,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33663954","id":"PMC_33663954","title":"Bcl6-Mediated Transcriptional Regulation of Follicular Helper T cells (TFH).","date":"2021","source":"Trends in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/33663954","citation_count":146,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23812097","id":"PMC_23812097","title":"MicroRNAs of the miR-17∼92 family are critical regulators of T(FH) differentiation.","date":"2013","source":"Nature immunology","url":"https://pubmed.ncbi.nlm.nih.gov/23812097","citation_count":144,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"14695314","id":"PMC_14695314","title":"Biallelic inactivation of fumarate hydratase (FH) occurs in nonsyndromic uterine leiomyomas but is rare in other tumors.","date":"2004","source":"The American journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/14695314","citation_count":135,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18366737","id":"PMC_18366737","title":"The FH mutation database: an online database of fumarate hydratase mutations involved in the MCUL (HLRCC) tumor syndrome and congenital fumarase deficiency.","date":"2008","source":"BMC medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/18366737","citation_count":126,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12183404","id":"PMC_12183404","title":"Few FH mutations in sporadic counterparts of tumor types observed in hereditary leiomyomatosis and renal cell cancer families.","date":"2002","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/12183404","citation_count":125,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29556002","id":"PMC_29556002","title":"Recognition of microbial viability via TLR8 drives TFH cell differentiation and vaccine responses.","date":"2018","source":"Nature immunology","url":"https://pubmed.ncbi.nlm.nih.gov/29556002","citation_count":121,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28887367","id":"PMC_28887367","title":"Tfr cells lack IL-2Rα but express decoy IL-1R2 and IL-1Ra and suppress the IL-1-dependent activation of Tfh cells.","date":"2017","source":"Science immunology","url":"https://pubmed.ncbi.nlm.nih.gov/28887367","citation_count":120,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28620008","id":"PMC_28620008","title":"PTEN, DICER1, FH, and Their Associated Tumor Susceptibility Syndromes: Clinical Features, Genetics, and Surveillance Recommendations in Childhood.","date":"2017","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/28620008","citation_count":119,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20944673","id":"PMC_20944673","title":"Follicular lymphoma cell niche: identification of a preeminent IL-4-dependent T(FH)-B cell axis.","date":"2010","source":"Leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/20944673","citation_count":117,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34234346","id":"PMC_34234346","title":"Metabolic control of TFH cells and humoral immunity by phosphatidylethanolamine.","date":"2021","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/34234346","citation_count":111,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9645949","id":"PMC_9645949","title":"cyk-1: a C. elegans FH gene required for a late step in embryonic cytokinesis.","date":"1998","source":"Journal of cell science","url":"https://pubmed.ncbi.nlm.nih.gov/9645949","citation_count":110,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21398687","id":"PMC_21398687","title":"Novel FH mutations in families with hereditary leiomyomatosis and renal cell cancer (HLRCC) and patients with isolated type 2 papillary renal cell carcinoma.","date":"2011","source":"Journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/21398687","citation_count":106,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31519812","id":"PMC_31519812","title":"Inhibition of IL-2 responsiveness by IL-6 is required for the generation of GC-TFH cells.","date":"2019","source":"Science immunology","url":"https://pubmed.ncbi.nlm.nih.gov/31519812","citation_count":103,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25797312","id":"PMC_25797312","title":"Clinical experience of scoring criteria for Familial Hypercholesterolaemia (FH) genetic testing in Wales.","date":"2015","source":"Atherosclerosis","url":"https://pubmed.ncbi.nlm.nih.gov/25797312","citation_count":102,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33536617","id":"PMC_33536617","title":"Dynamic regulation of TFH selection during the germinal centre reaction.","date":"2021","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/33536617","citation_count":88,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35817844","id":"PMC_35817844","title":"Targeting TFH cells in human diseases and vaccination: rationale and practice.","date":"2022","source":"Nature immunology","url":"https://pubmed.ncbi.nlm.nih.gov/35817844","citation_count":83,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"37689804","id":"PMC_37689804","title":"Fumarate hydratase (FH) and cancer: a paradigm of oncometabolism.","date":"2023","source":"British journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/37689804","citation_count":82,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31451659","id":"PMC_31451659","title":"Excessive CD11c+Tbet+ B cells promote aberrant TFH differentiation and affinity-based germinal center selection in lupus.","date":"2019","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/31451659","citation_count":82,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28179607","id":"PMC_28179607","title":"Half a Century Tales of Familial Hypercholesterolemia (FH) in Japan.","date":"2017","source":"Journal of atherosclerosis and thrombosis","url":"https://pubmed.ncbi.nlm.nih.gov/28179607","citation_count":80,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12535738","id":"PMC_12535738","title":"Electronegative LDL of FH subjects: chemical characterization and induction of chemokine release from human endothelial cells.","date":"2003","source":"Atherosclerosis","url":"https://pubmed.ncbi.nlm.nih.gov/12535738","citation_count":80,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28592321","id":"PMC_28592321","title":"Characterization of MED12, HMGA2, and FH alterations reveals molecular variability in uterine smooth muscle tumors.","date":"2017","source":"Molecular cancer","url":"https://pubmed.ncbi.nlm.nih.gov/28592321","citation_count":76,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16343504","id":"PMC_16343504","title":"Autosomal recessive hypercholesterolemia (ARH) and homozygous familial hypercholesterolemia (FH): a phenotypic comparison.","date":"2005","source":"Atherosclerosis","url":"https://pubmed.ncbi.nlm.nih.gov/16343504","citation_count":76,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33221382","id":"PMC_33221382","title":"Immunophenotyping in pemphigus reveals a TH17/TFH17 cell-dominated immune response promoting desmoglein1/3-specific autoantibody production.","date":"2020","source":"The Journal of allergy and clinical immunology","url":"https://pubmed.ncbi.nlm.nih.gov/33221382","citation_count":74,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28692065","id":"PMC_28692065","title":"Increased cathepsin S in Prdm1-/- dendritic cells alters the TFH cell repertoire and contributes to lupus.","date":"2017","source":"Nature immunology","url":"https://pubmed.ncbi.nlm.nih.gov/28692065","citation_count":72,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28391914","id":"PMC_28391914","title":"The Montreal-FH-SCORE: A new score to predict cardiovascular events in familial hypercholesterolemia.","date":"2016","source":"Journal of clinical lipidology","url":"https://pubmed.ncbi.nlm.nih.gov/28391914","citation_count":71,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27865860","id":"PMC_27865860","title":"Human regulatory B cells control the TFH cell response.","date":"2016","source":"The Journal of allergy and clinical immunology","url":"https://pubmed.ncbi.nlm.nih.gov/27865860","citation_count":69,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"2837085","id":"PMC_2837085","title":"Characterization of six partial deletions in the low-density-lipoprotein (LDL) receptor gene causing familial hypercholesterolemia (FH).","date":"1988","source":"American journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/2837085","citation_count":68,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33068561","id":"PMC_33068561","title":"Dual function of Langerhans cells in skin TSLP-promoted TFH differentiation in mouse atopic dermatitis.","date":"2020","source":"The Journal of allergy and clinical immunology","url":"https://pubmed.ncbi.nlm.nih.gov/33068561","citation_count":66,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30575739","id":"PMC_30575739","title":"Ezh2 programs TFH differentiation by integrating phosphorylation-dependent activation of Bcl6 and polycomb-dependent repression of p19Arf.","date":"2018","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/30575739","citation_count":61,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28457909","id":"PMC_28457909","title":"Critical Role for Skin-Derived Migratory DCs and Langerhans Cells in TFH and GC Responses after Intradermal Immunization.","date":"2017","source":"The Journal of investigative dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/28457909","citation_count":60,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15220362","id":"PMC_15220362","title":"Molecular genetic analysis of FIH-1, FH, and SDHB candidate tumour suppressor genes in renal cell carcinoma.","date":"2004","source":"Journal of clinical pathology","url":"https://pubmed.ncbi.nlm.nih.gov/15220362","citation_count":57,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34663810","id":"PMC_34663810","title":"Dysregulation of TFH-B-TRM lymphocyte cooperation is associated with unfavorable anti-PD-1 responses in EGFR-mutant lung cancer.","date":"2021","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/34663810","citation_count":54,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25161192","id":"PMC_25161192","title":"Human factor H (FH) impairs protective meningococcal anti-FHbp antibody responses and the antibodies enhance FH binding.","date":"2014","source":"mBio","url":"https://pubmed.ncbi.nlm.nih.gov/25161192","citation_count":53,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32332730","id":"PMC_32332730","title":"Ethanol consumption inhibits TFH cell responses and the development of autoimmune arthritis.","date":"2020","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/32332730","citation_count":52,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25105836","id":"PMC_25105836","title":"The Succinated Proteome of FH-Mutant Tumours.","date":"2014","source":"Metabolites","url":"https://pubmed.ncbi.nlm.nih.gov/25105836","citation_count":52,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30874359","id":"PMC_30874359","title":"TFH cells in bystander and cognate interactions with B cells.","date":"2019","source":"Immunological reviews","url":"https://pubmed.ncbi.nlm.nih.gov/30874359","citation_count":49,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10781834","id":"PMC_10781834","title":"Complement factor H: sequence analysis of 221 kb of human genomic DNA containing the entire fH, fHR-1 and fHR-3 genes.","date":"2000","source":"Molecular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/10781834","citation_count":49,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9781014","id":"PMC_9781014","title":"Concentrations of the atherogenic Lp(a) are elevated in FH.","date":"1998","source":"European journal of human genetics : EJHG","url":"https://pubmed.ncbi.nlm.nih.gov/9781014","citation_count":49,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29332133","id":"PMC_29332133","title":"Fumarate hydratase (FH) deficiency in uterine leiomyomas: recognition by histological features versus blind immunoscreening.","date":"2018","source":"Virchows Archiv : an international journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/29332133","citation_count":48,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35715365","id":"PMC_35715365","title":"Genomic Profiling and Response to Immune Checkpoint Inhibition plus Tyrosine Kinase Inhibition in FH-Deficient Renal Cell Carcinoma.","date":"2022","source":"European urology","url":"https://pubmed.ncbi.nlm.nih.gov/35715365","citation_count":46,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32344191","id":"PMC_32344191","title":"The emerging role of T follicular helper (TFH) cells in aging: Influence on the immune frailty.","date":"2020","source":"Ageing research reviews","url":"https://pubmed.ncbi.nlm.nih.gov/32344191","citation_count":41,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31118930","id":"PMC_31118930","title":"Rare Functional Variants in Complement Genes and Anti-FH Autoantibodies-Associated aHUS.","date":"2019","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/31118930","citation_count":41,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27187686","id":"PMC_27187686","title":"MED12 mutations and FH inactivation are mutually exclusive in uterine leiomyomas.","date":"2016","source":"British journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/27187686","citation_count":40,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"2831865","id":"PMC_2831865","title":"New variant of low density lipoprotein receptor gene. FH-Tonami.","date":"1988","source":"Arteriosclerosis (Dallas, Tex.)","url":"https://pubmed.ncbi.nlm.nih.gov/2831865","citation_count":40,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29079178","id":"PMC_29079178","title":"The utility of SDHB and FH immunohistochemistry in patients evaluated for hereditary paraganglioma-pheochromocytoma syndromes.","date":"2017","source":"Human pathology","url":"https://pubmed.ncbi.nlm.nih.gov/29079178","citation_count":39,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"36989114","id":"PMC_36989114","title":"MAIT cells activate dendritic cells to promote TFH cell differentiation and induce humoral immunity.","date":"2023","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/36989114","citation_count":38,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25836309","id":"PMC_25836309","title":"In vitro assay to sensitively measure T(FR) suppressive capacity and T(FH) stimulation of B cell responses.","date":"2015","source":"Methods in molecular biology (Clifton, N.J.)","url":"https://pubmed.ncbi.nlm.nih.gov/25836309","citation_count":37,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"37255402","id":"PMC_37255402","title":"FH Variant Pathogenicity Promotes Purine Salvage Pathway Dependence in Kidney Cancer.","date":"2023","source":"Cancer discovery","url":"https://pubmed.ncbi.nlm.nih.gov/37255402","citation_count":36,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34031386","id":"PMC_34031386","title":"The metabolic hormone leptin promotes the function of TFH cells and supports vaccine responses.","date":"2021","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/34031386","citation_count":36,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31863069","id":"PMC_31863069","title":"HnRNP F/H associate with hTERC and telomerase holoenzyme to modulate telomerase function and promote cell proliferation.","date":"2019","source":"Cell death and differentiation","url":"https://pubmed.ncbi.nlm.nih.gov/31863069","citation_count":34,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34623911","id":"PMC_34623911","title":"Tox2 is required for the maintenance of GC TFH cells and the generation of memory TFH cells.","date":"2021","source":"Science advances","url":"https://pubmed.ncbi.nlm.nih.gov/34623911","citation_count":33,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30429287","id":"PMC_30429287","title":"Complement Inhibitor CRIg/FH Ameliorates Renal Ischemia Reperfusion Injury via Activation of PI3K/AKT Signaling.","date":"2018","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/30429287","citation_count":33,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30949068","id":"PMC_30949068","title":"Current Status of Familial Hypercholesterolemia in China: A Need for Patient FH Registry Systems.","date":"2019","source":"Frontiers in physiology","url":"https://pubmed.ncbi.nlm.nih.gov/30949068","citation_count":32,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31444830","id":"PMC_31444830","title":"Fumarate hydratase FH c.1431_1433dupAAA (p.Lys477dup) variant is not associated with cancer including renal cell carcinoma.","date":"2019","source":"Human mutation","url":"https://pubmed.ncbi.nlm.nih.gov/31444830","citation_count":32,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29234687","id":"PMC_29234687","title":"Delivery of CR2-fH Using AAV Vector Therapy as Treatment Strategy in the Mouse Model of Choroidal Neovascularization.","date":"2017","source":"Molecular therapy. Methods & clinical development","url":"https://pubmed.ncbi.nlm.nih.gov/29234687","citation_count":32,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33372138","id":"PMC_33372138","title":"TFH cells depend on Tcf1-intrinsic HDAC activity to suppress CTLA4 and guard B-cell help function.","date":"2021","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/33372138","citation_count":31,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33012073","id":"PMC_33012073","title":"Human pregnancy levels of estrogen and progesterone contribute to humoral immunity by activating TFH /B cell axis.","date":"2020","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/33012073","citation_count":31,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35624463","id":"PMC_35624463","title":"CXCL13 expressed on inflamed cerebral blood vessels recruit IL-21 producing TFH cells to damage neurons following stroke.","date":"2022","source":"Journal of neuroinflammation","url":"https://pubmed.ncbi.nlm.nih.gov/35624463","citation_count":29,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"38363680","id":"PMC_38363680","title":"Stem-like progenitor and terminally differentiated TFH-like CD4+ T cell exhaustion in the tumor microenvironment.","date":"2024","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/38363680","citation_count":28,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25676468","id":"PMC_25676468","title":"Binding of Complement Factor H (FH) Decreases Protective Anti-FH Binding Protein Antibody Responses of Infant Rhesus Macaques Immunized With a Meningococcal Serogroup B Vaccine.","date":"2015","source":"The Journal of infectious diseases","url":"https://pubmed.ncbi.nlm.nih.gov/25676468","citation_count":28,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28288038","id":"PMC_28288038","title":"Immunohistochemical Characterization of Fumarate Hydratase (FH) and Succinate Dehydrogenase (SDH) in Cutaneous Leiomyomas for Detection of Familial Cancer Syndromes.","date":"2017","source":"The American journal of surgical pathology","url":"https://pubmed.ncbi.nlm.nih.gov/28288038","citation_count":28,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34353877","id":"PMC_34353877","title":"Gene of the month: FH.","date":"2021","source":"Journal of clinical pathology","url":"https://pubmed.ncbi.nlm.nih.gov/34353877","citation_count":26,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"38427718","id":"PMC_38427718","title":"TGF-β specifies TFH versus TH17 cell fates in murine CD4+ T cells through c-Maf.","date":"2024","source":"Science immunology","url":"https://pubmed.ncbi.nlm.nih.gov/38427718","citation_count":25,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34678832","id":"PMC_34678832","title":"Comparison of 2SC, AKR1B10, and FH Antibodies as Potential Biomarkers for FH-deficient Uterine Leiomyomas.","date":"2022","source":"The American journal of surgical pathology","url":"https://pubmed.ncbi.nlm.nih.gov/34678832","citation_count":23,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34512670","id":"PMC_34512670","title":"Follicular Helper T (TFH) Cell Targeting by TLR8 Signaling For Improving HBsAg-Specific B Cell Response In Chronic Hepatitis B Patients.","date":"2021","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/34512670","citation_count":22,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17520677","id":"PMC_17520677","title":"Increased HIF1 alpha in SDH and FH deficient tumors does not cause microsatellite instability.","date":"2007","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/17520677","citation_count":22,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23578468","id":"PMC_23578468","title":"[Diagnostic and treatment of familial hypercholesterolemia (FH) in adult: guidelines from the New French Society of Atherosclerosis (NSFA)].","date":"2013","source":"Presse medicale (Paris, France : 1983)","url":"https://pubmed.ncbi.nlm.nih.gov/23578468","citation_count":22,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"36964178","id":"PMC_36964178","title":"Aiolos represses CD4+ T cell cytotoxic programming via reciprocal regulation of TFH transcription factors and IL-2 sensitivity.","date":"2023","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/36964178","citation_count":21,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29213121","id":"PMC_29213121","title":"The Genetic Spectrum of Familial Hypercholesterolemia (FH) in the Iranian Population.","date":"2017","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/29213121","citation_count":21,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35288096","id":"PMC_35288096","title":"Genomic and Metabolic Hallmarks of SDH- and FH-deficient Renal Cell Carcinomas.","date":"2022","source":"European urology focus","url":"https://pubmed.ncbi.nlm.nih.gov/35288096","citation_count":21,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"1609792","id":"PMC_1609792","title":"A large deletion in the LDL receptor gene--the cause of familial hypercholesterolemia in three Italian families: a study that dates back to the 17th century (FH-Pavia).","date":"1992","source":"American journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/1609792","citation_count":21,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31711505","id":"PMC_31711505","title":"Circulating PCSK9 and cardiovascular events in FH patients with standard lipid-lowering therapy.","date":"2019","source":"Journal of translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/31711505","citation_count":20,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31752725","id":"PMC_31752725","title":"The new complement inhibitor CRIg/FH ameliorates lupus nephritis in lupus-prone MRL/lpr mice.","date":"2019","source":"BMC nephrology","url":"https://pubmed.ncbi.nlm.nih.gov/31752725","citation_count":20,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28868092","id":"PMC_28868092","title":"The Spectrum of Familial Hypercholesterolemia (FH) in Saudi Arabia: Prime Time for Patient FH Registry.","date":"2017","source":"The open cardiovascular medicine journal","url":"https://pubmed.ncbi.nlm.nih.gov/28868092","citation_count":19,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"36961907","id":"PMC_36961907","title":"The transcription factor Mef2d regulates B:T synapse-dependent GC-TFH differentiation and IL-21-mediated humoral immunity.","date":"2023","source":"Science immunology","url":"https://pubmed.ncbi.nlm.nih.gov/36961907","citation_count":18,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35177472","id":"PMC_35177472","title":"Strong influenza-induced TFH generation requires CD4 effectors to recognize antigen locally and receive signals from continuing infection.","date":"2022","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/35177472","citation_count":18,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"37409534","id":"PMC_37409534","title":"Prevalence of FH-Causing Variants and Impact on LDL-C Concentration in European, South Asian, and African Ancestry Groups of the UK Biobank-Brief Report.","date":"2023","source":"Arteriosclerosis, thrombosis, and vascular biology","url":"https://pubmed.ncbi.nlm.nih.gov/37409534","citation_count":17,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29790226","id":"PMC_29790226","title":"Comparative analysis of AKT and the related biomarkers in uterine leiomyomas with MED12, HMGA2, and FH mutations.","date":"2018","source":"Genes, chromosomes & cancer","url":"https://pubmed.ncbi.nlm.nih.gov/29790226","citation_count":17,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16961764","id":"PMC_16961764","title":"Modulation of high alcohol drinking in the inbred Fawn-Hooded (FH/Wjd) rat strain: implications for treatment.","date":"2006","source":"Addiction biology","url":"https://pubmed.ncbi.nlm.nih.gov/16961764","citation_count":16,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23199546","id":"PMC_23199546","title":"Maternal familial hypercholesterolaemia (FH) confers altered haemostatic profile in offspring with and without FH.","date":"2012","source":"Thrombosis research","url":"https://pubmed.ncbi.nlm.nih.gov/23199546","citation_count":16,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15936009","id":"PMC_15936009","title":"Altered composition of HDL3 in FH subjects causing a HDL subfraction with less atheroprotective function.","date":"2005","source":"Clinica chimica acta; international journal of clinical chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/15936009","citation_count":16,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28380354","id":"PMC_28380354","title":"The Drosophila hnRNP F/H Homolog Glorund Uses Two Distinct RNA-Binding Modes to Diversify Target Recognition.","date":"2017","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/28380354","citation_count":15,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"37802996","id":"PMC_37802996","title":"SARS-CoV-2 spike-specific TFH cells exhibit unique responses in infected and vaccinated individuals.","date":"2023","source":"Signal transduction and targeted therapy","url":"https://pubmed.ncbi.nlm.nih.gov/37802996","citation_count":15,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"36455002","id":"PMC_36455002","title":"Kidney tumors associated with germline mutations of FH and SDHB show a CpG island methylator phenotype (CIMP).","date":"2022","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/36455002","citation_count":15,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31156642","id":"PMC_31156642","title":"TH1-Polarized TFH Cells Delay Naturally-Acquired Immunity to Malaria.","date":"2019","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/31156642","citation_count":14,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28645073","id":"PMC_28645073","title":"Analysis of LDLR variants from homozygous FH patients carrying multiple mutations in the LDLR gene.","date":"2017","source":"Atherosclerosis","url":"https://pubmed.ncbi.nlm.nih.gov/28645073","citation_count":14,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35687696","id":"PMC_35687696","title":"Clonal evolution and TCR specificity of the human TFH cell response to Plasmodium falciparum CSP.","date":"2022","source":"Science immunology","url":"https://pubmed.ncbi.nlm.nih.gov/35687696","citation_count":13,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35901597","id":"PMC_35901597","title":"Exploring the mechanism of berberine-mediated Tfh cell immunosuppression.","date":"2022","source":"Phytomedicine : international journal of phytotherapy and phytopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/35901597","citation_count":13,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22425645","id":"PMC_22425645","title":"The impact of severe LDL receptor mutations on SREBP-pathway regulation in homozygous familial hypercholesterolemia (FH).","date":"2012","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/22425645","citation_count":13,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33858092","id":"PMC_33858092","title":"Zn2+-dependent enhancement of Atrazine biodegradation by Klebsiella variicola FH-1.","date":"2021","source":"Journal of hazardous materials","url":"https://pubmed.ncbi.nlm.nih.gov/33858092","citation_count":13,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"36269833","id":"PMC_36269833","title":"HIRA loss transforms FH-deficient cells.","date":"2022","source":"Science advances","url":"https://pubmed.ncbi.nlm.nih.gov/36269833","citation_count":12,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"40528028","id":"PMC_40528028","title":"Mitochondrial DNA oxidation propagates autoimmunity by enabling plasmacytoid dendritic cells to induce TFH differentiation.","date":"2025","source":"Nature immunology","url":"https://pubmed.ncbi.nlm.nih.gov/40528028","citation_count":11,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27556703","id":"PMC_27556703","title":"Generation of TALEN-mediated FH knockout rat model.","date":"2016","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/27556703","citation_count":11,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32823190","id":"PMC_32823190","title":"Prevalence Of familial hypercholeSTerolaemia (FH) in Italian Patients with coronary artERy disease: The POSTER study.","date":"2020","source":"Atherosclerosis","url":"https://pubmed.ncbi.nlm.nih.gov/32823190","citation_count":11,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15761122","id":"PMC_15761122","title":"Complement factor H polymorphism in age-related macular degeneration.","date":"2005","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/15761122","citation_count":3310,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15761121","id":"PMC_15761121","title":"Complement factor H polymorphism and age-related macular degeneration.","date":"2005","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/15761121","citation_count":1965,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15761120","id":"PMC_15761120","title":"Complement factor H variant increases the risk of age-related macular degeneration.","date":"2005","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/15761120","citation_count":1959,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15870199","id":"PMC_15870199","title":"A common haplotype in the complement regulatory gene factor H (HF1/CFH) predisposes individuals to age-related macular degeneration.","date":"2005","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/15870199","citation_count":1646,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12477932","id":"PMC_12477932","title":"Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences.","date":"2002","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/12477932","citation_count":1479,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"28514442","id":"PMC_28514442","title":"Architecture of the human interactome defines protein communities and disease networks.","date":"2017","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/28514442","citation_count":1085,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"26496610","id":"PMC_26496610","title":"A human interactome in three quantitative dimensions organized by stoichiometries and abundances.","date":"2015","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/26496610","citation_count":1015,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"20595690","id":"PMC_20595690","title":"Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype.","date":"2010","source":"Clinical journal of the American Society of Nephrology : CJASN","url":"https://pubmed.ncbi.nlm.nih.gov/20595690","citation_count":773,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"14702039","id":"PMC_14702039","title":"Complete sequencing and characterization of 21,243 full-length human cDNAs.","date":"2003","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/14702039","citation_count":754,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"33961781","id":"PMC_33961781","title":"Dual proteome-scale networks reveal cell-specific remodeling of the human interactome.","date":"2021","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/33961781","citation_count":705,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"21873635","id":"PMC_21873635","title":"Phylogenetic-based propagation of functional annotations within the Gene Ontology consortium.","date":"2011","source":"Briefings in bioinformatics","url":"https://pubmed.ncbi.nlm.nih.gov/21873635","citation_count":656,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"23455636","id":"PMC_23455636","title":"Seven new loci associated with age-related macular degeneration.","date":"2013","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/23455636","citation_count":649,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"16174643","id":"PMC_16174643","title":"Hypothetical LOC387715 is a second major susceptibility gene for age-related macular degeneration, contributing independently of complement factor H to disease risk.","date":"2005","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/16174643","citation_count":640,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"16621965","id":"PMC_16621965","title":"Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome.","date":"2006","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/16621965","citation_count":555,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"21399633","id":"PMC_21399633","title":"Genome-wide association study identifies susceptibility loci for IgA nephropathy.","date":"2011","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/21399633","citation_count":522,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"23702979","id":"PMC_23702979","title":"Immunology of age-related macular degeneration.","date":"2013","source":"Nature reviews. Immunology","url":"https://pubmed.ncbi.nlm.nih.gov/23702979","citation_count":514,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"8125298","id":"PMC_8125298","title":"Oligo-capping: a simple method to replace the cap structure of eukaryotic mRNAs with oligoribonucleotides.","date":"1994","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/8125298","citation_count":492,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"16936732","id":"PMC_16936732","title":"Common variation in three genes, including a noncoding variant in CFH, strongly influences risk of age-related macular degeneration.","date":"2006","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/16936732","citation_count":489,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15163532","id":"PMC_15163532","title":"The human complement factor H: functional roles, genetic variations and disease associations.","date":"2004","source":"Molecular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/15163532","citation_count":447,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"21979047","id":"PMC_21979047","title":"Complement factor H binds malondialdehyde epitopes and protects from oxidative stress.","date":"2011","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/21979047","citation_count":445,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15489334","id":"PMC_15489334","title":"The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).","date":"2004","source":"Genome research","url":"https://pubmed.ncbi.nlm.nih.gov/15489334","citation_count":438,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"20385819","id":"PMC_20385819","title":"Genetic variants near TIMP3 and high-density lipoprotein-associated loci influence susceptibility to age-related macular degeneration.","date":"2010","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/20385819","citation_count":433,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"9551389","id":"PMC_9551389","title":"Genetic studies into inherited and sporadic hemolytic uremic syndrome.","date":"1998","source":"Kidney international","url":"https://pubmed.ncbi.nlm.nih.gov/9551389","citation_count":390,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"20385826","id":"PMC_20385826","title":"Genome-wide association study of advanced age-related macular degeneration identifies a role of the hepatic lipase gene (LIPC).","date":"2010","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/20385826","citation_count":376,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"16335952","id":"PMC_16335952","title":"Human plasma N-glycoproteome analysis by immunoaffinity subtraction, hydrazide chemistry, and mass spectrometry.","date":"2005","source":"Journal of proteome research","url":"https://pubmed.ncbi.nlm.nih.gov/16335952","citation_count":350,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"17767156","id":"PMC_17767156","title":"Variation in complement factor 3 is associated with risk of age-related macular degeneration.","date":"2007","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/17767156","citation_count":344,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"16785547","id":"PMC_16785547","title":"The meningococcal vaccine candidate GNA1870 binds the complement regulatory protein factor H and enhances serum resistance.","date":"2006","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/16785547","citation_count":330,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"20580090","id":"PMC_20580090","title":"Complement control protein factor H: the good, the bad, and the inadequate.","date":"2010","source":"Molecular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/20580090","citation_count":319,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"18596911","id":"PMC_18596911","title":"Systemic complement activation in age-related macular degeneration.","date":"2008","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/18596911","citation_count":310,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"2963625","id":"PMC_2963625","title":"The complete amino acid sequence of human complement factor H.","date":"1988","source":"The Biochemical journal","url":"https://pubmed.ncbi.nlm.nih.gov/2963625","citation_count":309,"is_preprint":false,"source_track":"gene2pubmed"}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":51571,"output_tokens":2910,"usd":0.099182},"stage2":{"model":"claude-opus-4-6","input_tokens":6274,"output_tokens":2550,"usd":0.14268},"total_usd":0.535582,"stage1_batch_id":"msgbatch_0118RScg3WGaGkaZRtWZbtce","stage2_batch_id":"msgbatch_01Cpfzvtbj42aqp5oYZ5Te2s","note":"batch pricing = 50% of standard","round2_stage1":{"model":"claude-sonnet-4-6","input_tokens":63604,"output_tokens":4309,"usd":0.127723},"round2_rules_fired":"R3","round2_stage2":{"model":"claude-opus-4-6","input_tokens":7493,"output_tokens":2928,"usd":0.165997}},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2002,\n      \"finding\": \"Germline loss-of-function mutations in FH (fumarate hydratase), an enzyme of the tricarboxylic acid cycle, cause hereditary leiomyomatosis and renal cell cancer (HLRCC); FH acts as a tumor suppressor, with fumarate hydratase activity reduced in lymphoblastoid cells from affected individuals and very low or absent in tumors, consistent with biallelic inactivation.\",\n      \"method\": \"Critical recombinant mapping, germline mutation identification, transcript screening, enzymatic activity assays in lymphoblastoid cells and tumors\",\n      \"journal\": \"Nature genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — enzymatic activity assay combined with mutation identification; foundational paper with 1204 citations replicated across many subsequent studies\",\n      \"pmids\": [\"11865300\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"Biallelic somatic inactivation of FH (fumarate hydratase) occurs in nonsyndromic uterine leiomyomas, confirming FH as the true target of 1q43 deletions in these tumors.\",\n      \"method\": \"Loss of heterozygosity analysis, FH mutation screening (splice site and missense mutations identified), sequencing of tumor DNA\",\n      \"journal\": \"The American journal of pathology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — direct mutation analysis with LOH in tumors; replicated the tumor suppressor model\",\n      \"pmids\": [\"14695314\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"Fumarate (which accumulates due to FH loss) competitively inhibits multiple α-ketoglutarate (α-KG)-dependent dioxygenases, including histone demethylases (KDMs), TET family 5mC hydroxylases, and prolyl hydroxylases, leading to broad inhibition of histone and DNA demethylation; FH knockdown elevates intracellular fumarate and reproduces these inhibitory effects, and ectopic expression of tumor-derived FH mutants inhibits histone demethylation and 5mC hydroxylation.\",\n      \"method\": \"In vitro competitive inhibition assays with purified α-KG-dependent dioxygenases, siRNA knockdown of FH with measurement of intracellular fumarate/succinate levels, ectopic expression of FH mutants, histone methylation and 5mC hydroxylation assays\",\n      \"journal\": \"Genes & development\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro reconstitution of competitive inhibition + genetic KD + mutant overexpression; 920 citations across multiple labs\",\n      \"pmids\": [\"22677546\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"FH germline mutations cause loss of fumarate hydratase enzymatic activity in pheochromocytoma/paraganglioma tumors (demonstrated by somatic second-allele inactivation), and FH-deficient tumors show reduced 5-hydroxymethylcytosine (5-hmC) and positive S-(2-succinyl)-cysteine (2SC) staining, indicating epigenetic deregulation analogous to SDHB-deficient tumors.\",\n      \"method\": \"Direct sequencing and multiplex ligation-dependent probe amplification for FH mutations, immunohistochemical staining for 5-hmC and 2SC as functional readouts of FH loss\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — functional enzymatic loss confirmed by second-allele inactivation and protein succination marker; single cohort study\",\n      \"pmids\": [\"24334767\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"FH loss in HLRCC tumors leads to high-level fumarate accumulation that drives succination (S-(2-succino)cysteine formation, 2SC) of multiple cysteine-containing proteins; a proteomic screen identified 60 succinated proteins in FH-mutant tumors and HLRCC-derived cell lines, including GAPDH, KEAP1, and mitochondrial aconitase (ACO2), with succination at functionally significant cysteine residues.\",\n      \"method\": \"Mass spectrometry-based proteomics succination screen on FH-mutant tumor and cancer cell line lysates; bioinformatic enrichment analysis\",\n      \"journal\": \"Metabolites\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — mass spectrometry proteomics identifying succination targets in disease-relevant material; single study\",\n      \"pmids\": [\"25105836\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"In FH-deficient HLRCC tumors, HIF1α is stabilized (moderately or highly in 67% of cases), consistent with fumarate inhibiting prolyl hydroxylases that normally target HIF1α for degradation; however, HIF1α stabilization does not cause microsatellite instability or repress MSH2 in these tumors.\",\n      \"method\": \"Immunohistochemical analysis of HIF1α in HLRCC tumors; microsatellite instability testing; MSH2 expression analysis\",\n      \"journal\": \"International journal of cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — IHC in tumor tissue demonstrating HIF1α stabilization as functional consequence of FH loss; single study\",\n      \"pmids\": [\"17520677\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"TALEN-mediated homozygous FH knockout is embryonically lethal in rats, demonstrating that FH is essential for embryonic development; heterozygous FH knockout (FH+/-) rats show hematopoietic and kidney dysfunction, and anaplastic lesions in kidney tubular epithelial cells positive for Ki67, p53, and Sox9.\",\n      \"method\": \"TALEN-mediated gene knockout in rat zygotes, breeding experiments, histopathology, immunohistochemistry (Ki67, p53, Sox9), clinical hematology and biochemical analyses\",\n      \"journal\": \"Oncotarget\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — in vivo genetic knockout model with defined phenotypic readout; single study\",\n      \"pmids\": [\"27556703\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"HIRA loss enhances proliferation and invasion of Fh1-deficient cells in vitro and in vivo; mechanistically, Hira loss activates MYC and its target genes, increasing nucleotide metabolism specifically in Fh1-deficient cells, independent of HIRA's histone chaperone activity, thereby transforming FH-deficient premalignant cells.\",\n      \"method\": \"Genome-wide CRISPR-Cas9 screen in Fh1-deficient mouse cells, in vitro proliferation/invasion assays, in vivo tumor models, MYC target gene expression analysis, genetic rescue experiments\",\n      \"journal\": \"Science advances\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — genome-wide screen plus functional validation in vitro and in vivo with mechanistic follow-up; single study\",\n      \"pmids\": [\"36269833\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Fumarate accumulation due to FH loss blocks de novo purine biosynthesis, rendering FH-deficient cells reliant on the purine salvage pathway for proliferation; genetic or pharmacologic inhibition of purine salvage (e.g., 6-mercaptopurine) reduces HLRCC tumor growth in vivo. Quantification of catalytic efficiencies of 74 FH variants of uncertain significance showed that over half are enzymatically inactive.\",\n      \"method\": \"Enzymatic activity quantification of 74 FH VUS, HLRCC cell line panel with FH variants, metabolic profiling of fumarate and purine pathway metabolites, genetic inhibition of purine salvage, in vivo xenograft tumor growth assays, pharmacological inhibition with 6-mercaptopurine\",\n      \"journal\": \"Cancer discovery\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — enzymatic assays + cell biology + in vivo functional validation with multiple orthogonal approaches; single rigorous study\",\n      \"pmids\": [\"37255402\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"FH-deficient renal cell carcinomas (FHRCC) demonstrate a CpG island methylator phenotype (CIMP) with extensive and relatively uniform hypermethylation, consistent with fumarate-mediated inhibition of TET enzymes; hypermethylation and transcriptional downregulation of HIF pathway genes (HIF3A, CITED4), WNT pathway gene SFRP1, and OVOL1 were demonstrated.\",\n      \"method\": \"Genome-wide methylation profiling (Illumina HumanMethylation450 BeadChip) of FH-mutant RCC tumors and normal samples; combined methylation and mRNA expression analysis\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — genome-wide methylation profiling correlating FH loss with CIMP in tumor tissue; single study\",\n      \"pmids\": [\"36455002\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"FH (fumarate hydratase) catalyzes the reversible hydration of fumarate to L-malate in the TCA cycle; biallelic germline mutations result in fumaric aciduria (severe neurological disorder), and heterozygous germline mutations cause HLRCC through multiple oncogenic mechanisms including aerobic glycolysis promotion, pseudohypoxia induction, post-translational protein succination, and impairment of DNA damage repair by homologous recombination.\",\n      \"method\": \"Review synthesizing enzymatic function, mutation analysis, and multiple mechanistic studies\",\n      \"journal\": \"Journal of clinical pathology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — review consolidating enzymatic function and mechanistic evidence from multiple primary studies\",\n      \"pmids\": [\"34353877\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"FH (fumarate hydratase) is a TCA cycle enzyme that catalyzes the reversible hydration of fumarate to L-malate; its loss-of-function causes accumulation of fumarate, which acts as an oncometabolite by competitively inhibiting α-KG-dependent dioxygenases (histone demethylases, TET enzymes, prolyl hydroxylases), leading to epigenetic reprogramming and HIF stabilization, while also driving irreversible succination of cysteine residues in key proteins (KEAP1, GAPDH, ACO2) and blocking de novo purine biosynthesis to create purine salvage pathway dependence, collectively promoting tumorigenesis in HLRCC.\"\n}\n```\n\n--- ROUND 2 (R2/R3, augmented corpus) ---\n\nI need to carefully classify each paper before extracting discoveries.\n\n**Classification:**\n\nThe gene query is FH = **Fumarate Hydratase** (the TCA cycle enzyme, tumor suppressor in HLRCC).\n\nHowever, the corpus is heavily contaminated with:\n- **TFH** (T follicular helper cells) papers — these use \"TFH\" as an abbreviation, NOT the FH gene\n- **FH** = Familial Hypercholesterolemia papers — alias collision (different gene/disease)\n- **CFH/FH** = Complement Factor H papers — alias collision (different gene)\n- **FH/Wjd rat** — Fawn-Hooded rat strain, not the gene\n- **cyk-1** C. elegans paper — this is an FH gene (formin homology), NOT fumarate hydratase — SYMBOL COLLISION (different protein family)\n- **hnRNP F/H** papers — alias collision\n- **Klebsiella FH-1** — microbial strain, not the gene\n\n**KEEP papers** (about fumarate hydratase FH gene/protein):\n- PMID:11865300, 22677546, 24334767, 14695314, 18366737, 12183404, 21398687, 28592321, 25105836, 37689804, 37255402, 34353877, 36269833, 27556703, 17520677, 29332133, 28288038, 34678832, 28645073, 29790226, 36455002, 35288096, 28620008, 15220362\n\n**EXCLUDE** all TFH cell papers, FH=Familial Hypercholesterolemia papers, CFH=Complement Factor H papers, cyk-1 formin paper (PMID:9645949), hnRNP papers, Fawn-Hooded rat, Klebsiella FH-1, and the large additional gene2pubmed set (all CFH/AMD/complement or generic cDNA).\n\n```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2002,\n      \"finding\": \"Germline mutations in the FH gene (encoding fumarate hydratase, a TCA cycle enzyme) cause dominantly inherited uterine fibroids, cutaneous leiomyomata, and papillary renal cell cancer (HLRCC syndrome). Leiomyomatosis-associated mutations predict absent/truncated protein or substitutions of conserved amino acids; fumarate hydratase enzymatic activity is reduced in lymphoblastoid cells from affected individuals and is very low or absent in tumors, establishing FH as a tumor suppressor.\",\n      \"method\": \"Positional cloning, germline mutation identification, enzymatic activity assay in lymphoblastoid cells and tumor tissue\",\n      \"journal\": \"Nature genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — enzymatic activity measured directly in patient cells and tumors, replicated across multiple families, foundational discovery paper with >1200 citations\",\n      \"pmids\": [\"11865300\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"Biallelic inactivation of FH (fumarate hydratase) is rare in sporadic counterparts of HLRCC-associated tumor types; one uterine leiomyosarcoma, one cutaneous leiomyoma, and one soft tissue sarcoma showed biallelic FH inactivation, with the sarcoma representing purely somatic inactivation, confirming FH as a classical two-hit tumor suppressor.\",\n      \"method\": \"Mutation screening, loss of heterozygosity analysis across multiple tumor types\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — LOH plus sequencing, single study but broad tumor panel\",\n      \"pmids\": [\"12183404\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"Somatic FH mutations (a splice site change causing exon 4 deletion and a missense mutation Ala196Thr) occur in nonsyndromic uterine leiomyomas showing LOH at 1q43, confirming FH as a bona fide target of 1q43 deletions and demonstrating that biallelic somatic FH inactivation drives non-hereditary leiomyoma formation.\",\n      \"method\": \"LOH analysis, Sanger sequencing of FH in 299 malignant tumors and 153 leiomyomas\",\n      \"journal\": \"The American journal of pathology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — LOH plus mutation sequencing, single study\",\n      \"pmids\": [\"14695314\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"FH-deficient (HLRCC) tumors show moderately or highly stabilized HIF1α in 67% of cases, consistent with fumarate accumulation inhibiting prolyl hydroxylases (PHDs) and causing pseudohypoxia; however, HIF1α stabilization in these tumors does not cause microsatellite instability or loss of MSH2, dissociating HIF1α stabilization from mismatch repair deficiency in this context.\",\n      \"method\": \"Immunohistochemistry for HIF1α and MSH2 in HLRCC tumor series; microsatellite instability analysis\",\n      \"journal\": \"International journal of cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — IHC with functional readout (MSI analysis) on defined tumor cohort, single study\",\n      \"pmids\": [\"17520677\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"Fumarate (accumulated due to FH loss) and succinate are competitive inhibitors of multiple α-ketoglutarate (α-KG)-dependent dioxygenases, including histone demethylases (KDMs), TET family 5mC hydroxylases, and prolyl hydroxylases. Knockdown of FH elevates intracellular fumarate which broadly inhibits α-KG-dependent dioxygenase activity; ectopic expression of tumor-derived FH mutants inhibits histone demethylation and 5mC hydroxylation, leading to genome-wide hypermethylation.\",\n      \"method\": \"In vitro enzymatic inhibition assays, siRNA knockdown of FH with metabolite measurement, ectopic expression of FH mutants, histone methylation and 5-hmC assays\",\n      \"journal\": \"Genes & development\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro reconstituted enzyme inhibition plus cellular loss-of-function with orthogonal epigenetic readouts; >900 citations, multiple methods\",\n      \"pmids\": [\"22677546\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Germline FH mutations predispose to malignant pheochromocytoma and paraganglioma. FH-deficient PCC/PGLs show somatic second-hit inactivation, loss of fumarate hydratase enzymatic activity, low 5-hydroxymethylcytosine (5-hmC) levels (consistent with TET inhibition by fumarate), and positive 2SC (S-(2-succino)cysteine) immunostaining indicative of protein succination, demonstrating the same epigenetic deregulation pattern as SDHB-mutated tumors.\",\n      \"method\": \"Germline sequencing, MLPA for large deletions, immunohistochemistry for 5-hmC and 2SC, enzymatic activity confirmed by second-hit somatic analysis\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multi-method (sequencing + IHC biomarkers + enzymatic activity loss), large international cohort, strong evidence\",\n      \"pmids\": [\"24334767\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Proteomic screening of FH-mutant tumors and HLRCC-derived cell lines identified 60 proteins with succinated cysteine residues (S-(2-succino)cysteine, 2SC), a non-enzymatic irreversible modification of cysteine by fumarate. Key succinated targets include GAPDH, KEAP1, and mitochondrial aconitase (ACO2) at functionally significant cysteines; bioinformatic analysis shows most succinated targets are involved in redox signaling, demonstrating that fumarate acts as an oncometabolite through widespread protein succination.\",\n      \"method\": \"Mass spectrometry-based proteomic succination screen on FH-mutant tumor tissue and HLRCC cell lines\",\n      \"journal\": \"Metabolites\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 — MS-based proteomic identification of modification sites, single study on tumor/cell line material\",\n      \"pmids\": [\"25105836\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Homozygous FH knockout in rats is embryonically lethal; heterozygous FH+/- rats display hematopoietic and kidney dysfunction, and small foci of anaplastic tubular epithelial cells in the kidney that are positive for Ki67, p53, and Sox9, demonstrating that partial FH loss causes renal dysplasia and functional organ defects in vivo.\",\n      \"method\": \"TALEN-mediated FH gene knockout rat model; histopathology, immunohistochemistry (Ki67, p53, Sox9), hematology and biochemical analyses\",\n      \"journal\": \"Oncotarget\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — defined genetic model with multiple phenotypic readouts, single study\",\n      \"pmids\": [\"27556703\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Somatic MED12 mutations and biallelic FH inactivation are mutually exclusive in both HLRCC-associated and sporadic uterine leiomyomas, and FH-deficient tumors cluster separately from MED12-mutant tumors by global gene expression profiling, indicating they represent distinct molecular subtypes driven by different oncogenic pathways.\",\n      \"method\": \"MED12 mutation screening, 2SC immunohistochemistry for FH deficiency, Affymetrix gene expression arrays\",\n      \"journal\": \"British journal of cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — mutual exclusivity demonstrated across comprehensive tumor series with transcriptomic validation\",\n      \"pmids\": [\"27187686\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"MED12, HMGA2, and FH alterations are mutually exclusive driver alterations in uterine smooth muscle tumors. FH-deficient tumors are the predominant driver in leiomyomas with bizarre nuclei, while MED12 mutations predominate in conventional and mitotically active leiomyomas; presence of these leiomyoma driver alterations in ~one-third of leiomyosarcomas suggests potential progression from precursor lesions.\",\n      \"method\": \"FH immunohistochemistry (2SC), MED12 mutation screening, HMGA2 expression analysis across 210 uterine smooth muscle tumors\",\n      \"journal\": \"Molecular cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — large tumor series with multiple molecular assays, single study\",\n      \"pmids\": [\"28592321\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"FH encodes a mitochondrial enzyme catalyzing the reversible hydration of fumarate to L-malate in the TCA cycle. FH deficiency drives oncogenesis through multiple mechanisms: promotion of aerobic glycolysis (Warburg effect), induction of pseudohypoxia (via PHD inhibition and HIF stabilization), post-translational protein succination, and impairment of DNA damage repair by homologous recombination.\",\n      \"method\": \"Review synthesizing mechanistic experimental data from multiple prior studies\",\n      \"journal\": \"Journal of clinical pathology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — comprehensive review synthesizing established mechanisms; mechanistic claims grounded in cited experimental literature\",\n      \"pmids\": [\"34353877\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"HIRA loss enhances proliferation and invasion of Fh1-deficient cells in vitro and in vivo. Mechanistically, Hira loss activates MYC and its target genes, specifically increasing nucleotide metabolism in Fh1-deficient cells independent of HIRA's histone chaperone activity, identifying a synthetic vulnerabilty in FH-deficient cells.\",\n      \"method\": \"Genome-wide CRISPR-Cas9 screen in Fh1-deficient mouse cells; in vitro proliferation/invasion assays; in vivo tumor models; transcriptomic analysis of MYC targets; nucleotide metabolism assays\",\n      \"journal\": \"Science advances\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — genome-wide unbiased CRISPR screen plus mechanistic follow-up with multiple orthogonal methods in vitro and in vivo\",\n      \"pmids\": [\"36269833\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Fumarate accumulation due to FH loss blocks de novo purine biosynthesis, rendering FH-deficient cells dependent on the purine salvage pathway for proliferation. Genetic or pharmacologic inhibition of purine salvage (including 6-mercaptopurine) reduced HLRCC tumor growth in vivo. Functional characterization of 74 FH variants of uncertain significance showed that over half are enzymatically inactive.\",\n      \"method\": \"Catalytic efficiency measurement of 74 FH variants; isotope tracing of purine biosynthesis; genetic knockdown and pharmacologic inhibition of purine salvage in HLRCC cell lines; in vivo xenograft models\",\n      \"journal\": \"Cancer discovery\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro enzymatic assays for 74 variants plus metabolic tracing plus in vivo validation; multiple orthogonal methods\",\n      \"pmids\": [\"37255402\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"FH loss, via fumarate accumulation, activates multiple oncogenic cascades contributing to tumorigenesis including pseudohypoxia, epigenetic reprogramming through α-KG-dependent dioxygenase inhibition, protein succination, and metabolic rewiring; the tissue-specific aggressive behavior of HLRCC cancers remains under investigation.\",\n      \"method\": \"Review integrating mechanistic experimental findings from the field\",\n      \"journal\": \"British journal of cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — comprehensive mechanistic review; individual mechanisms grounded in cited experimental work\",\n      \"pmids\": [\"37689804\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"Novel FH mutations across 56 HLRCC families and isolated papillary RCC patients demonstrated that all 21 novel mutations are deleterious by significant reduction of FH enzymatic activity; reduced FH activity was the functional correlate for pathogenicity of missense, frameshift, nonsense, splice site, and deletion variants.\",\n      \"method\": \"Sanger sequencing, functional FH enzymatic activity assay in patient-derived samples\",\n      \"journal\": \"Journal of medical genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1–2 — direct enzymatic activity measurement for novel variants, large clinical series\",\n      \"pmids\": [\"21398687\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"FH (fumarate hydratase) is a mitochondrial TCA cycle enzyme that catalyzes the reversible hydration of fumarate to L-malate; germline loss-of-function mutations cause HLRCC by acting as a classical two-hit tumor suppressor, with the resulting fumarate accumulation driving oncogenesis through competitive inhibition of α-KG-dependent dioxygenases (causing histone/DNA hypermethylation and pseudohypoxia), widespread protein succination of cysteine residues (modifying GAPDH, KEAP1, ACO2 and ~60 other proteins), blockade of de novo purine biosynthesis forcing purine salvage pathway dependence, and impairment of homologous recombination DNA repair—while complete FH loss is embryonically lethal and HIRA co-loss specifically activates MYC-driven nucleotide metabolism as a synthetic vulnerability in FH-deficient tumors.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"FH (fumarate hydratase) is a TCA cycle enzyme that catalyzes the reversible hydration of fumarate to L-malate and functions as a tumor suppressor whose loss drives oncogenesis through fumarate-dependent metabolic reprogramming. Accumulated fumarate competitively inhibits α-ketoglutarate-dependent dioxygenases—including histone demethylases, TET family 5-methylcytosine hydroxylases, and HIF prolyl hydroxylases—resulting in a CpG island methylator phenotype, aberrant histone methylation, and HIF1α stabilization [PMID:22677546, PMID:36455002, PMID:17520677]. Fumarate also drives irreversible succination of functionally critical cysteine residues on proteins including KEAP1, GAPDH, and mitochondrial aconitase (ACO2), and blocks de novo purine biosynthesis, creating a therapeutically exploitable dependence on the purine salvage pathway [PMID:25105836, PMID:37255402]. Germline loss-of-function mutations in FH cause hereditary leiomyomatosis and renal cell cancer (HLRCC) and biallelic mutations cause fumaric aciduria [PMID:11865300, PMID:34353877].\",\n  \"teleology\": [\n    {\n      \"year\": 2002,\n      \"claim\": \"Identification of FH as the causative tumor suppressor gene in HLRCC established that a core TCA cycle enzyme could function as a tumor suppressor, with biallelic inactivation eliminating fumarate hydratase activity in tumors.\",\n      \"evidence\": \"Germline mutation identification, enzymatic activity assays in lymphoblastoid cells and tumors from HLRCC families\",\n      \"pmids\": [\"11865300\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism by which loss of enzymatic activity promotes tumorigenesis was unknown\", \"Whether FH loss alone is sufficient for transformation was not established\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Demonstration of biallelic somatic FH inactivation in nonsyndromic uterine leiomyomas confirmed FH as the functional target of 1q43 deletions beyond the hereditary cancer syndrome.\",\n      \"evidence\": \"LOH analysis and FH mutation screening in sporadic uterine leiomyomas\",\n      \"pmids\": [\"14695314\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"The downstream oncogenic consequences of fumarate accumulation remained undefined\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Observation that HIF1α is stabilized in FH-deficient HLRCC tumors linked fumarate accumulation to pseudohypoxia signaling through prolyl hydroxylase inhibition.\",\n      \"evidence\": \"Immunohistochemical analysis of HIF1α in HLRCC tumor tissue\",\n      \"pmids\": [\"17520677\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Causal link between fumarate and prolyl hydroxylase inhibition was not directly tested in this study\", \"Contribution of HIF stabilization versus other fumarate effects to tumorigenesis was unclear\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Biochemical reconstitution revealed that fumarate competitively inhibits multiple α-KG-dependent dioxygenases—histone demethylases, TET enzymes, and prolyl hydroxylases—establishing the oncometabolite mechanism whereby FH loss causes broad epigenetic reprogramming.\",\n      \"evidence\": \"In vitro competitive inhibition assays with purified dioxygenases, siRNA knockdown of FH measuring intracellular metabolites, ectopic expression of tumor-derived FH mutants\",\n      \"pmids\": [\"22677546\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Relative contribution of each dioxygenase class to tumorigenesis was not resolved\", \"In vivo validation of epigenetic changes driving transformation was limited\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Extension of the FH tumor suppressor model to pheochromocytoma/paraganglioma, with reduced 5-hmC and positive 2SC staining, showed that fumarate-driven epigenetic and succination consequences generalize across FH-deficient tumor types.\",\n      \"evidence\": \"Germline and somatic FH mutation analysis with immunohistochemistry for 5-hmC and 2SC in pheo/PGL tumors\",\n      \"pmids\": [\"24334767\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Small cohort; prevalence of FH mutations in pheo/PGL not fully defined\", \"Whether succination markers are specific to FH loss versus SDH loss was not resolved\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Proteomic identification of 60 succinated proteins in FH-mutant tumors—including GAPDH, KEAP1, and ACO2 at functionally critical cysteines—revealed that post-translational protein succination is a major effector mechanism of fumarate accumulation.\",\n      \"evidence\": \"Mass spectrometry-based proteomics on FH-mutant tumor and HLRCC cell line lysates\",\n      \"pmids\": [\"25105836\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Functional consequences of succination for most of the 60 identified targets were not characterized\", \"Quantitative thresholds of fumarate required for succination were not defined\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Homozygous FH knockout is embryonically lethal in rats and heterozygous loss causes hematopoietic dysfunction and proliferative kidney lesions, establishing FH as essential for development and confirming haploinsufficiency phenotypes in vivo.\",\n      \"evidence\": \"TALEN-mediated FH knockout in rats with histopathology and immunohistochemistry\",\n      \"pmids\": [\"27556703\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether kidney lesions progress to renal cell carcinoma was not shown\", \"Mechanism of hematopoietic dysfunction was not defined\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Genome-wide methylation profiling of FH-deficient renal cell carcinomas confirmed a CpG island methylator phenotype with transcriptional silencing of HIF pathway and WNT pathway genes, directly linking fumarate-mediated TET inhibition to an epigenomic driver phenotype.\",\n      \"evidence\": \"Illumina methylation array profiling of FH-mutant RCC tumors with integrated mRNA expression analysis\",\n      \"pmids\": [\"36455002\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Causal contribution of individual silenced genes to tumor maintenance was not tested\", \"Comparison with other CIMP-driven cancers was limited\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"A CRISPR screen revealed that HIRA loss cooperates with Fh1 deficiency to promote transformation via MYC-driven nucleotide metabolism, identifying a second-hit event required for FH-deficient cells to become fully malignant.\",\n      \"evidence\": \"Genome-wide CRISPR-Cas9 screen in Fh1-deficient mouse cells with in vivo validation and MYC target gene analysis\",\n      \"pmids\": [\"36269833\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"HIRA loss frequency in human HLRCC tumors was not established\", \"Mechanism by which HIRA loss activates MYC independent of histone chaperone activity was not defined\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Demonstration that fumarate blocks de novo purine biosynthesis and creates dependence on the purine salvage pathway revealed a targetable metabolic vulnerability in FH-deficient tumors; systematic enzymatic profiling of 74 FH variants classified their pathogenicity.\",\n      \"evidence\": \"Enzymatic activity quantification of FH VUS, metabolic profiling, genetic and pharmacological inhibition of purine salvage in HLRCC xenografts\",\n      \"pmids\": [\"37255402\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Clinical efficacy of purine salvage inhibitors in HLRCC patients is untested\", \"Whether purine salvage dependence is universal across all FH-deficient tumor types is unknown\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"The relative contribution of each fumarate-driven mechanism (epigenetic reprogramming, HIF stabilization, protein succination, purine biosynthesis blockade) to tumor initiation versus maintenance remains unresolved, and the cooperating genetic events required for full transformation of FH-deficient cells are incompletely mapped.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No systematic dissection of individual oncogenic mechanisms in isogenic models\", \"In vivo therapeutic validation of purine salvage or epigenetic targeting in human HLRCC is lacking\", \"Structural basis for fumarate's differential effects on specific dioxygenase family members is not established\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0016829\", \"supporting_discovery_ids\": [0, 2, 8, 10]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005739\", \"supporting_discovery_ids\": [0, 10]},\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [2, 8]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [0, 2, 8, 10]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [0, 1, 3, 8]},\n      {\"term_id\": \"R-HSA-4839726\", \"supporting_discovery_ids\": [2, 9]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"KEAP1\", \"GAPDH\", \"ACO2\"],\n    \"other_free_text\": []\n  }\n}\n```\n\n--- ROUND 2 (R2/R3, augmented corpus) ---\n\n```json\n{\n  \"mechanistic_narrative\": \"FH encodes fumarate hydratase, a mitochondrial TCA cycle enzyme that catalyzes the reversible hydration of fumarate to L-malate and functions as a tumor suppressor whose biallelic inactivation drives oncogenesis through accumulation of the oncometabolite fumarate. Fumarate competitively inhibits α-ketoglutarate-dependent dioxygenases—including histone demethylases (KDMs), TET hydroxylases, and prolyl hydroxylases—causing genome-wide DNA and histone hypermethylation and pseudohypoxic HIF1α stabilization, while also non-enzymatically succinating cysteine residues on ~60 proteins including GAPDH, KEAP1, and ACO2 [PMID:22677546, PMID:25105836]. Germline heterozygous FH loss-of-function mutations cause hereditary leiomyomatosis and renal cell cancer (HLRCC) syndrome, with tumors showing classical two-hit inactivation and near-complete loss of enzymatic activity [PMID:11865300, PMID:21398687], and also predispose to pheochromocytoma and paraganglioma [PMID:24334767]. FH deficiency blocks de novo purine biosynthesis, creating dependence on the purine salvage pathway that represents a therapeutic vulnerability, while co-deletion of the histone chaperone HIRA activates MYC-driven nucleotide metabolism as an additional synthetic vulnerability in FH-null cells [PMID:37255402, PMID:36269833].\",\n  \"teleology\": [\n    {\n      \"year\": 2002,\n      \"claim\": \"Positional cloning established FH as the causative gene for HLRCC syndrome and demonstrated that germline mutations abolish or reduce fumarate hydratase enzymatic activity, identifying the first TCA cycle enzyme to function as a bona fide tumor suppressor.\",\n      \"evidence\": \"Linkage mapping, mutation identification, and enzymatic activity assays in patient lymphoblastoid cells and tumors across multiple HLRCC families\",\n      \"pmids\": [\"11865300\", \"12183404\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Mechanism by which loss of a metabolic enzyme drives tumorigenesis was unknown\",\n        \"Whether FH loss contributes to sporadic (non-syndromic) tumors was unclear\",\n        \"No animal model existed to test consequences of FH loss in vivo\"\n      ]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"The discovery of biallelic somatic FH inactivation in sporadic uterine leiomyomas confirmed FH as a driver of non-hereditary tumors and showed that FH-deficient leiomyomas represent a distinct molecular subtype from MED12-mutant tumors.\",\n      \"evidence\": \"LOH analysis and Sanger sequencing of FH in sporadic leiomyomas; later confirmed by mutual exclusivity with MED12 and HMGA2 alterations across large tumor series\",\n      \"pmids\": [\"14695314\", \"27187686\", \"28592321\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Whether FH-deficient leiomyomas can progress to leiomyosarcoma remained uncertain\",\n        \"Tissue-specific mechanisms favoring smooth muscle tumorigenesis were not defined\"\n      ]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Demonstration of HIF1α stabilization in FH-deficient tumors provided the first evidence that fumarate accumulation inhibits prolyl hydroxylases to create pseudohypoxia, linking metabolite accumulation to an oncogenic signaling phenotype.\",\n      \"evidence\": \"HIF1α immunohistochemistry in HLRCC tumor series with microsatellite instability analysis\",\n      \"pmids\": [\"17520677\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Whether HIF1α stabilization was the primary oncogenic driver or one of several parallel mechanisms was unclear\",\n        \"Direct measurement of PHD inhibition by fumarate in these tumors was lacking\"\n      ]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Systematic functional characterization of 21 novel FH mutations confirmed that reduced enzymatic activity is the universal pathogenic mechanism across all mutation types, establishing a functional assay framework for variant classification.\",\n      \"evidence\": \"Sanger sequencing and direct FH enzymatic activity assay across 56 HLRCC families\",\n      \"pmids\": [\"21398687\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Many variants of uncertain significance remained uncharacterized\",\n        \"Quantitative relationship between residual FH activity and tumor risk was not established\"\n      ]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"The mechanistic basis of fumarate-driven oncogenesis was broadened beyond pseudohypoxia by demonstrating that fumarate competitively inhibits the entire family of α-KG-dependent dioxygenases, including histone demethylases and TET enzymes, causing genome-wide epigenetic reprogramming.\",\n      \"evidence\": \"In vitro enzymatic inhibition assays, siRNA knockdown of FH with metabolite quantification, ectopic expression of tumor-derived FH mutants with histone methylation and 5-hmC readouts\",\n      \"pmids\": [\"22677546\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Which specific epigenetic changes are causally required for transformation versus bystanders was not resolved\",\n        \"Whether epigenetic changes are reversible upon FH reconstitution was not tested\"\n      ]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"FH was established as a pheochromocytoma/paraganglioma susceptibility gene with the same fumarate-driven epigenetic and succination signatures as seen in SDH-mutant tumors, expanding the clinical spectrum of FH deficiency beyond HLRCC.\",\n      \"evidence\": \"Germline sequencing, MLPA, immunohistochemistry for 5-hmC and 2SC in FH-mutant PCC/PGL cohort\",\n      \"pmids\": [\"24334767\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Why FH mutations only rarely cause PCC/PGL compared to SDH mutations was unexplained\",\n        \"Genotype-phenotype correlations distinguishing HLRCC-only from HLRCC+PCC/PGL families were not established\"\n      ]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Proteomic profiling revealed that fumarate-mediated protein succination is widespread (~60 targets), irreversibly modifying functionally critical cysteines on GAPDH, KEAP1, and ACO2, establishing protein succination as a major effector mechanism of FH-deficient oncogenesis alongside epigenetic reprogramming.\",\n      \"evidence\": \"Mass spectrometry-based succination screen on FH-mutant tumor tissue and HLRCC cell lines\",\n      \"pmids\": [\"25105836\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"The individual contributions of specific succination events to tumorigenesis were not dissected\",\n        \"Whether succination targets differ across tissue types was not tested\"\n      ]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"An FH-knockout rat model demonstrated that complete FH loss is embryonically lethal while heterozygous loss causes renal dysplasia and hematopoietic defects, providing the first in vivo genetic evidence that partial FH deficiency has cell-autonomous pathological consequences in kidney epithelium.\",\n      \"evidence\": \"TALEN-mediated FH knockout in rats with histopathology, IHC, and hematologic/biochemical analysis\",\n      \"pmids\": [\"27556703\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"The rat model did not recapitulate frank tumor formation characteristic of HLRCC\",\n        \"Whether the renal dysplastic foci progress to carcinoma with aging was not determined\"\n      ]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"A genome-wide CRISPR screen identified HIRA loss as a synthetic vulnerability partner in FH-deficient cells, operating through MYC activation and enhanced nucleotide metabolism independent of HIRA's histone chaperone function, revealing a non-canonical cooperation between chromatin regulation and metabolic rewiring.\",\n      \"evidence\": \"CRISPR-Cas9 screen in Fh1-null mouse cells; in vitro/in vivo validation; transcriptomic and nucleotide metabolism assays\",\n      \"pmids\": [\"36269833\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Whether HIRA loss occurs spontaneously in human HLRCC tumors was not established\",\n        \"The mechanism linking HIRA loss to MYC activation was not fully defined\",\n        \"Therapeutic targeting of this synthetic interaction was not demonstrated\"\n      ]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Fumarate accumulation was shown to block de novo purine biosynthesis by inhibiting adenylosuccinate lyase, creating a targetable dependence on the purine salvage pathway that was exploited therapeutically with 6-mercaptopurine in vivo; in parallel, systematic enzymatic characterization of 74 FH variants of uncertain significance classified over half as pathogenic.\",\n      \"evidence\": \"Isotope tracing of purine metabolism, enzymatic characterization of 74 FH variants, genetic and pharmacologic purine salvage inhibition in HLRCC xenografts\",\n      \"pmids\": [\"37255402\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Clinical efficacy of purine salvage inhibition in HLRCC patients has not been tested\",\n        \"Whether purine synthesis blockade cooperates with epigenetic or succination mechanisms in driving tumor phenotypes is unresolved\"\n      ]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"The tissue-specific determinants of aggressive FH-deficient tumorigenesis (e.g., why HLRCC renal tumors are particularly lethal) and the relative causal contributions of epigenetic reprogramming, protein succination, and metabolic rewiring to tumor initiation versus progression remain unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"No genetically faithful HLRCC mouse model recapitulates full-spectrum renal cell carcinoma\",\n        \"Causal hierarchy among pseudohypoxia, epigenetic changes, succination, and purine metabolism disruption is not established\",\n        \"Tissue-specific cofactors that determine tumor spectrum in FH mutation carriers are unknown\"\n      ]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0016829\", \"supporting_discovery_ids\": [0, 4, 12, 14]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005739\", \"supporting_discovery_ids\": [0, 10]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [0, 4, 12]},\n      {\"term_id\": \"R-HSA-4839726\", \"supporting_discovery_ids\": [4, 5]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [0, 5, 12]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\n      \"KEAP1\",\n      \"GAPDH\",\n      \"ACO2\",\n      \"HIRA\",\n      \"HIF1A\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}